Literature DB >> 12579521

Effects of erythropoietin and pentoxifylline on the oxidant and antioxidant systems in the experimental short bowel syndrome.

Tevfik Noyan1, Onder Onem, M Ramazan Sekeroğlu, Burhan Köseoğlu, Haluk Dülger, Irfan Bayram, A Sadik Yalçinkaya, Vedat Bakan.   

Abstract

In this study, we investigated the effects of erythropoietin (Epo), and pentoxifylline (Ptx) on the oxidant and antioxidant systems in the experimental short bowel syndrome. Spraque-Dawley rats were divided into four groups and all animals underwent 75% small bowel resection. Group E was treated with 500 IU kg(- 1) Epo subcutaneously (s.c.), group P with 50 mg kg(- 1) day(- 1) s.c. Ptx and group E+P with 500 IU kg(- 1) s.c. Epo plus 50 mg kg(- 1) day(- 1) s.c. Ptx for a period of 28 days. In group C, which is the control group, no drug treatment was given. At the end of 28 days the experimented rats were killed and ileum samples excised for biochemical and histopathological testing. Malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels were determined in ileum homogenates. When compared to group C, the MDA and GSH-Px levels were significantly decreased (p < 0.05), but SOD activity was not changed (p > 0.05) in groups P and E+P, whereas both MDA and SOD and also GSH-Px activities were not changed significantly in group E (p > 0.05). The average villous length, crypt depth, muscular thickness and mucosal length were measured in all groups. The average crypt depth and mucosal length were statistically higher in the group P than group C (p < 0.001, p < 0.01, respectively). In addition, the crypt depth was statistically higher in both E and E+P groups as compared to group C (p < 0.001, p < 0.01, respectively). Therefore, our study indicates that Ptx may be more effective than Epo in reducing lipid peroxidation. Moreover, we considered that Ptx may give this protective effect by inhibiting the free oxygen radicals to a greater extent than developing the antioxidant capacity. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12579521     DOI: 10.1002/cbf.991

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  7 in total

1.  Exploration of early-life candidate biomarkers for childhood asthma using antibody arrays.

Authors:  Haili Xu; Timothy Radabaugh; Zhenqiang Lu; Michael Galligan; Dean Billheimer; Donata Vercelli; Anne L Wright; Terrence J Monks; Marilyn Halonen; Serrine S Lau
Journal:  Pediatr Allergy Immunol       Date:  2016-09-12       Impact factor: 6.377

2.  Effect of pentoxifylline and 5-fluorouracil/triamcinolone on laryngotracheal stenosis developing as a complication of tracheostomy: study in rats.

Authors:  Sema Koc; Halil Kıyıcı; Erkan Söğüt; Ahmet Eyibilen; Adnan Ekici; Nergis Salman
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-02-11       Impact factor: 2.503

3.  The effect of pentoxifylline on oxidative stress in CO2 pneumoperitoneum.

Authors:  Ayhan Dinckan; Emel Sahin; Mehmet Ogus; Kemal Emek; Saadet Gumuslu
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

4.  Antihyperglycemic, antihyperlipidemic and antioxidative potential of Prosopis cineraria bark.

Authors:  Nidhi Sharma; Veena Garg; Arpita Paul
Journal:  Indian J Clin Biochem       Date:  2010-05-27

5.  Therapeutic effect of captopril, pentoxifylline, and cordyceps sinensis in pre-hepatic portal hypertensive rats.

Authors:  Ahmed F Ahmed; Nabila N El-Maraghy; Rasha H Abdel Ghaney; Shimaa M Elshazly
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

6.  Evaluation of the Effect of Pentoxifylline on Cisplatin-Induced Testicular Toxicity in Rats.

Authors:  Ali Reza Fallahzadeh; Zohreh Rezaei; Hamid Reza Rahimi; Mehrazd Jafari Barmak; Hossein Sadeghi; Sadrollah Mehrabi; Seyed Mohammadreza Rabani; Iraj Ragerdi Kashani; Vahid Barati; Reza Mahmoudi
Journal:  Toxicol Res       Date:  2017-07-15

Review 7.  A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.

Authors:  Gomaa Mostafa-Hedeab; Hayder M Al-Kuraishy; Ali I Al-Gareeb; Philippe Jeandet; Hebatallah M Saad; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-04-29       Impact factor: 5.093

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.